Tisagenlecleucel In Primary CNS Lymphoma
brief summary
In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. . -The name of the study intervention is tisagenlecleucel.
detailed description
This research study is a Pilot Study, which is the first time investigators are examining this intervention in people with primary central nervous system lymphoma.
* The name of the study intervention is tisagenlecleucel. Tisagenlecleucel is an investigational treatment that uses the participants own immune cells, called T cells, to try to kill the cancerous cells * The research study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits. * The study treatment will be one day and participants will be followed for up to 2 years. * It is expected that about 12 people will take part in this research study
official title
Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System Lymphoma